রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications
JARDIMET 5/500 MG is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, especially when Metformin alone is not sufficient.
Pharmacology
Empagliflozin: An SGLT2 inhibitor that reduces blood sugar by increasing urinary glucose excretion.
Metformin: A biguanide that decreases hepatic glucose production, improves insulin sensitivity, and reduces intestinal glucose absorption.
Together, they offer complementary mechanisms to control blood glucose and provide cardiovascular benefits.
Dosage & Administration
Recommended dose: One tablet twice daily with meals to minimize gastrointestinal side effects.
Dosage may be adjusted depending on patient’s renal function and glucose response.
Interaction
May interact with diuretics, insulin, sulfonylureas (increase hypoglycemia risk), and drugs affecting renal function.
Contraindications
Severe renal impairment (eGFR < 30 ml/min/1.73m²)
Metabolic acidosis (including diabetic ketoacidosis)
Hypersensitivity to Empagliflozin or Metformin
Side Effects
Common: Genital infections, urinary tract infections, nausea, diarrhea, abdominal discomfort
Rare: Lactic acidosis (Metformin-related), dehydration, hypotension, hypoglycemia (when used with insulin)
Pregnancy & Lactation
Not recommended during pregnancy unless clearly needed.
Caution advised during breastfeeding; limited human data available.
Precautions & Warnings
Assess renal function before starting and periodically thereafter.
Discontinue temporarily before major surgery or radiologic studies involving iodinated contrast.
Advise patients on hydration and symptoms of lactic acidosis and genital infections.
Therapeutic Class
Combination Oral Antidiabetic
SGLT2 Inhibitor + Biguanide
Storage Conditions
Store at room temperature below 30°C. Protect from light, moisture, and heat. Keep out of reach of children.